Seksyen 1
Perintah ini bolehlah dinamakan Perintah Racun (Pindaan Senarai Racun) 2025.
Pindaan Jadual Pertama
P.U. (A)In force
Perintah Racun (Pindaan Senarai Racun) 2025
The full official text, structured for quick navigation. Copy any provision or jump straight to a section.
- Enacted
- 2025
- Sections
- 2
Perintah Racun (Pindaan Senarai Racun) 2025 is Malaysia P.U. (A), cited as P.U. (A) 460 2025, currently marked in force and first recorded in 2025.
Front matterCover and publication detailsOpenClose
P.U. (A) 460
WARTA KERAJAAN PERSEKUTUAN
FEDERAL GOVERNMENT
GAZETTE
PERINTAH RACUN
(PINDAAN SENARAI RACUN) 2025
POISONS
(AMENDMENT OF POISONS LIST) ORDER 2025
DISIARKAN OLEH/
JABATAN PEGUAM NEGARA/
ATTORNEY GENERAL’S CHAMBERS
P.U. (A) 460 2
AKTA RACUN 1952
PERINTAH RACUN (PINDAAN SENARAI RACUN) 2025
Opening note
Preamble
- PADA menjalankan kuasa yang diberikan oleh seksyen 6 Akta Racun 1952 [Akta 366], Menteri, selepas berunding dengan Lembaga Racun, membuat perintah yang berikut: Nama
Seksyen 2
Akta Racun 1952 dipinda dalam Jadual Pertama—
(i)
dengan memasukkan selepas butiran “Atracurium; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 3
Names
Bahagian I
Part I
Bahagian II
Part II
Exempt
Group A
Group B
Group C
Group D
“Avalglucosidase alfa
-
All preparations”;
(ii)
dengan memasukkan selepas butiran “Axitinib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Azacitidine
-
All preparations”;
(iii)
dengan memasukkan selepas butiran “Bortezomib” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Bosutinib
-
All preparations”;
P.U. (A) 460 4
(iv)
dengan memasukkan selepas butiran “Cladribine” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Clascoterone
-
All preparations”;
(v)
dengan memasukkan selepas butiran “Chlormethiazole; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Chlormethine
-
All preparations”;
(vi)
dengan memasukkan selepas butiran “Dehydroemetine; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 5
Names
Exempt
Group A
Group B
Group C
Group D
“Delamanid
-
All preparations”;
(vii)
dengan memasukkan selepas butiran “Escitalopram” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Eslicarbazepine acetate
-
All preparations”;
(viii)
dengan memasukkan selepas butiran “Finasteride” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 6
Names
Exempt
Group A
Group B
Group C
Group D
“Finerenone
-
All preparations”;
(ix)
dengan memasukkan selepas butiran “Losartan; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Lotilaner
-
All preparations”;
(x)
dengan memasukkan selepas butiran “Miconazole; its salts” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 7
Names
Exempt
Group A
Group B
Group C
Group D
“Midodrine hydrochloride
-
All preparations”;
(xi)
dengan memasukkan selepas butiran “Miglitol” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Milbemycin oxime
-
All preparations”;
(xii)
dalam senarai “Monoclonal antibody; includes the following:”—
dengan memasukkan selepas butiran “Emicizumab” butiran “Enfortumab”; dan dengan memasukkan selepas butiran “Mepolizumab” butiran “Mosunetuzumab”;
P.U. (A) 460 8
(xiii)
dengan memasukkan selepas butiran “Olaquindox” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Olipudase alfa
-
All preparations”;
(xiv)
dengan memasukkan selepas butiran “Omidenepag” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Onasemnogene abeparvovec
-
All preparations”;
(xv)
dengan memasukkan selepas butiran “Sodium cromoglycate” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 9
Names
Exempt
Group A
Group B
Group C
Group D
“Sodium hyaluronate
-
-
All preparations for parenteral administration”;
-
-
All preparations unless in Group C”;
(xvi)
dengan memasukkan selepas butiran “Tegaserod” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
Names
Exempt
Group A
Group B
Group C
Group D
“Tegoprazan
-
All preparations”; dan
(xvii)
dengan memasukkan selepas butiran “Tirofiban” dan butir-butir yang berhubungan dengannya butiran dan butir-butir yang berikut:
P.U. (A) 460 10
Names
Exempt
Group A
Group B
Group C
Group D
“Tirzepatide
-
All preparations”; dan
(i)
dalam senarai “Anthelmintics:”, dengan memasukkan selepas butiran “Melarsomine” butiran “Milbemycin oxime”;
(ii)
dalam senarai “Anticonvulsants:”, dengan memasukkan selepas butiran “Carbamazepine” butiran
“Eslicarbazepine acetate”;
(iii)
dalam senarai “Antidiabetics:”, dengan memasukkan selepas butiran “Sitagliptin” butiran “Tirzepatide”;
(iv)
dalam senarai “Antineoplastic agents and Immunosuppressants:”—
dengan memasukkan selepas butiran “Axitinib” butiran “Azacitidine”;
dengan memasukkan selepas butiran “Bortezomib” butiran “Bosutinib”;
P.U. (A) 460 11
dengan memasukkan selepas butiran “Chlorambucil; its salts” butiran “Chlormethine”;
dengan memasukkan selepas butiran “Durvalumab” butiran “Enfortumab”; dan dengan memasukkan selepas butiran “Mitoxantrone; its salts” butiran “Mosunetuzumab”;
(v)
dalam senarai “Antitubercular agents:”, dengan memasukkan selepas butiran “Bedaquiline” butiran
“Delamanid”;
(vi)
dalam senarai “Anti-ulcer agents:”, dengan memasukkan selepas butiran “Roxatidine” butiran “Tegoprazan”;
(vii)
dalam senarai “Diuretics:”, dengan memasukkan selepas butiran “Ethacrynic acid; its salts” butiran
“Finerenone”;
(viii)
dalam senarai “Sympathomimetic amines:”, dengan memasukkan selepas butiran “Indanazoline; its salts”
butiran “Midodrine hydrochloride”; dan
(ix)
dalam senarai “Miscellaneous:”—
dengan memasukkan selepas butiran “Atosiban” butiran “Avalglucosidase alfa”;
P.U. (A) 460 12
dengan memasukkan selepas butiran “Citicoline” butiran “Clascoterone”;
dengan memasukkan selepas butiran “Lonoctocog alfa” butiran “Lotilaner”;
dengan memasukkan selepas butiran “Olaquindox” butiran “Olipudase alfa”;
dengan memasukkan selepas butiran “Omidenepag” butiran “Onasemnogene abeparvovec”; dan
(F)
dengan memasukkan selepas butiran “Sodium cromoglycate” butiran “Sodium hyaluronate”.
Dibuat 21 November 2025
[KKM.600-18/2/95; PN(PU2)172/JLD.21]
DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD
Menteri Kesihatan
P.U. (A) 460 13
POISONS ACT 1952
POISONS (AMENDMENT OF POISONS LIST) ORDER 2025
Opening note
Preamble
- IN exercise of the powers conferred by section 6 of the Poisons Act 1952 [Act 366], the Minister, after consultation with the Poisons Board, makes the following order: Citation 1. This order may be cited as the Poisons (Amendment of Poisons List) Order 2025. Amendment of First Schedule 2. The Poisons Act 1952 is amended in the First Schedule —
(i)
by inserting after item “Atracurium; it salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Avalglucosidase alfa
-
All preparations”;
P.U. (A) 460 14
(ii)
by inserting after item “Axitinib” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Azacitidine
-
All preparations”;
(iii)
by inserting after item “Bortezomib” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Bosutinib
-
All preparations”;
(iv)
by inserting after item “Cladribine” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Clascoterone
-
All preparations”;
P.U. (A) 460 15
(v)
by inserting after item “Chlormethiazole; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Chlormethine
-
All preparations”;
(vi)
by inserting after item “Dehydroemetine; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Delamanid
-
All preparations”;
P.U. (A) 460 16
(vii)
by inserting after item “Escitalopram” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Eslicarbazepine acetate
-
All preparations”;
(viii)
by inserting after item “Finasteride” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Finerenone
-
All preparations”;
(ix)
by inserting after item “Losartan; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Lotilaner
-
All preparations”;
P.U. (A) 460 17
(x)
by inserting after item “Miconazole; its salts” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Midodrine hydrochloride
-
All preparations”;
(xi)
by inserting after item “Miglitol” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Milbemycin oxime
-
All preparations”;
(xii)
in the list of “Monoclonal antibody; includes the following:” —
by inserting after item “Emicizumab” item “Enfortumab”; and by inserting after item “Mepolizumab” item “Mosunetuzumab”;
P.U. (A) 460 18
(xiii)
by inserting after item “Olaquindox” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Olipudase alfa
-
All preparations”;
(xiv)
by inserting after item “Omidenepag” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Onasemnogene abeparvovec
-
All preparations”;
P.U. (A) 460 19
(xv)
by inserting after item “Sodium cromoglycate” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Sodium hyaluronate
-
-
All preparations for parenteral administration”;
-
-
All preparations unless in Group C”;
(xvi)
by inserting after item “Tegaserod” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tegoprazan
-
All preparations”; and
P.U. (A) 460 20
(xvii)
by inserting after item “Tirofiban” and the particulars relating to it the following item and particulars:
Names
Exempt
Group A
Group B
Group C
Group D
“Tirzepatide
-
All preparations”; and
(i)
in the list of “Anthelmintics:”, by inserting after item “Melarsomine” item “Milbemycin oxime”;
(ii)
in the list of “Anticonvulsants:”, by inserting after item “Carbamazepine” item “Eslicarbazepine acetate”;
(iii)
in the list of “Antidiabetics:”, by inserting after item “Sitagliptin” item “Tirzepatide”;
(iv)
in the list of “Antineoplastic agents and Immunosuppressants:”—
by inserting after item “Axitinib” item “Azacitidine”;
by inserting after item “Bortezomib” item “Bosutinib”;
P.U. (A) 460 21
by inserting after item “Chlorambucil; its salts” item “Chlormethine”;
by inserting after item “Durvalumab” item “Enfortumab”; and by inserting after item “Mitoxantrone; its salts” item “Mosunetuzumab”;
(v)
in the list of “Antitubercular agents:”, by inserting after item “Bedaquiline” item “Delamanid”;
(vi)
in the list of “Anti-ulcer agents:”, by inserting after item “Roxatidine” item “Tegoprazan”;
(vii)
in the list of “Diuretics:”, by inserting after item “Ethacrynic acid; its salts” item “Finerenone”;
(viii)
in the list of “Sympathomimetic amines:”, by inserting after item “Indanazoline; its salts” item “Midodrine hydrochloride”; and
(ix)
in the list of “Miscellaneous:” —
by inserting after item “Atosiban” item “Avalglucosidase alfa”;
by inserting after item “Citicoline” item “Clascoterone”;
P.U. (A) 460 22
by inserting after item “Lonoctocog alfa” item “Lotilaner”;
by inserting after item “Olaquindox” item “Olipudase alfa”;
by inserting after item “Omidenepag” item “Onasemnogene abeparvovec”; and
(F)
by inserting after item “Sodium cromoglycate” item “Sodium hyaluronate”.
Made 21 November 2025
[KKM.600-18/2/95; PN(PU2)172/JLD.21]
DATUK SERI DR. HAJI DZULKEFLY BIN AHMAD
Minister of Health
Common questions
- What is Perintah Racun (Pindaan Senarai Racun) 2025?
- Perintah Racun (Pindaan Senarai Racun) 2025 is Malaysia P.U. (A), cited as P.U. (A) 460 2025, currently marked in force and first recorded in 2025.
- Is Perintah Racun (Pindaan Senarai Racun) 2025 still in force?
- Yes — Perintah Racun (Pindaan Senarai Racun) 2025 is currently in force.
- When did Perintah Racun (Pindaan Senarai Racun) 2025 take effect?
- Perintah Racun (Pindaan Senarai Racun) 2025 was first recorded in 2025.
- How many sections does Perintah Racun (Pindaan Senarai Racun) 2025 have?
- Perintah Racun (Pindaan Senarai Racun) 2025 contains 2 sections.
- Where can I read the official version of Perintah Racun (Pindaan Senarai Racun) 2025?
- The official text of Perintah Racun (Pindaan Senarai Racun) 2025 is published at lom.agc.gov.my.
Something wrong on this page?
If one provision's text doesn't match the official source, use Suggest a fix beside that provision — it opens an editor next to the source document. For anything else — a missing amendment, a broken link, out-of-date content, or a removal request — report it here.